Orforglipron beats oral semaglutide in diabetes trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly's orforglipron beat oral semaglutide in a 52-week Phase 3 trial enrolling 1,698 adults with type 2 diabetes across six countries.
- Orforglipron cut HbA1c by an average of 1.71–1.91% versus 1.47% for oral semaglutide, from a baseline of 8.3%.
- Patients on orforglipron lost an average of 6.1–8.2 kg, compared with 5.3 kg for those on oral semaglutide.
- About 59% of orforglipron users reported gastrointestinal side effects versus 37–45% on semaglutide, with 10% discontinuing treatment versus 4–5%.
- As a small-molecule drug, orforglipron is cheaper and simpler to manufacture than peptide-based semaglutide and requires no refrigeration.
- Unlike oral semaglutide, orforglipron does not need to be taken on an empty stomach or require a 30-minute wait before eating.
- Orforglipron is still in trials for patients with obesity but without diabetes, and no head-to-head study against injectable GLP-1 drugs has been conducted.
Why it matters: For Eli Lilly, orforglipron's small-molecule, no-refrigeration profile could undercut oral semaglutide's market, particularly in low- and middle-income countries where cold-chain logistics are unreliable. But with a discontinuation rate of roughly 10% versus 4–5% for oral semaglutide, real-world adherence may blunt its commercial advantage in a tolerability-driven category.
